Display options
Cite
Dattola A, Cannizzaro MV, Mazzeo M, et al. Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data. Dermatol Ther (Heidelb). 2017;7(4):485-492doi: 10.1007/s13555-017-0208-z.
Dattola, A., Cannizzaro, M. V., Mazzeo, M., & Bianchi, L. (2017). Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data. Dermatology and therapy, 7(4), 485-492. https://doi.org/10.1007/s13555-017-0208-z
Dattola, Annunziata, et al. "Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data." Dermatology and therapy vol. 7,4 (2017): 485-492. doi: https://doi.org/10.1007/s13555-017-0208-z
Dattola A, Cannizzaro MV, Mazzeo M, Bianchi L. Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data. Dermatol Ther (Heidelb). 2017 Dec;7(4):485-492. doi: 10.1007/s13555-017-0208-z. Epub 2017 Nov 14. PMID: 29139035; PMCID: PMC5698207.
Copy Download .nbib Format: NLM
Share it on

Dermatol Ther (Heidelb). 2017 Dec;7(4):485-492. doi: 10.1007/s13555-017-0208-z. Epub 2017 Nov 14.

Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data.

Dermatology and therapy

Annunziata Dattola, Maria Vittoria Cannizzaro, Mauro Mazzeo, Luca Bianchi

Affiliations

  1. Department of Dermatology, University of Rome "Tor Vergata", Rome, Italy. [email protected].
  2. Department of Dermatology, University of Rome "Tor Vergata", Rome, Italy.

PMID: 29139035 PMCID: PMC5698207 DOI: 10.1007/s13555-017-0208-z

Abstract

INTRODUCTION: We present the results of real-life tests conducted in adults affected by psoriatic arthritis (PsA) with mild cutaneous involvement to evaluate the efficacy of certolizumab pegol (CZP), an anti-tumor necrosis factor-alpha agent approved in Europe for the treatment of rheumatoid arthritis and PsA.

METHODS: Assessments included an evaluation of the Psoriasis Area and Severity Index (PASI) and the Disease Activity Score computed on 44 joints (DAS-44) correlated to the erythrocyte sedimentation rate (ESR) (DAS44-ESR). A total of 41 patients (16 men, 25 women; mean age 59.8 ± 8 years) completed the study. Of these, 36 patients were affected by both PsA and psoriasis, and five patients were affected only by PsA. A total of 32 patients (group A) completed 3 months of treatment (W12), and 12 patients completed 6 months of treatment (W24) (group B).

RESULTS: The clinical efficacy of CZP was consistent on both the cutaneous and rheumatic components of the treatment. The mean PASI score decreased from 4.4 ± 4.7 at baseline (BL) to 2.3 ± 3.7 at W12 (group A), and from 5.1 ± 5.7 at BL to 0.8 ± 1.2 at W24 (group B). The DAS44-ESR decreased from 4.4 ± 0.6 at BL to a mean of 2.2 ± 0.9 at W12 (group A) and from 4.1 ± 0.6 at BL to a mean of 1.9 ± 0.5 at W24 (group B). No adverse events were reported.

CONCLUSION: Our results demonstrate that CZP can be used safely and effectively to treat both the cutaneous and joint components of PsA. However, long-term data are needed to confirm our preliminary observations.

Keywords: Anti-TNF-α; Biologics therapy; Certolizumab pegol; Psoriasis; Psoriatic arthritis; Real life data

References

  1. Rheumatology (Oxford). 2003 Dec;42(12 ):1460-8 - PubMed
  2. Value Health. 2014 Nov;17(7):A386 - PubMed
  3. Drug Des Devel Ther. 2013 Apr 15;7:339-48 - PubMed
  4. Arthritis Care Res (Hoboken). 2014 Jul;66(7):1085-92 - PubMed
  5. Reumatol Clin. 2011 Mar;6S3:S7-11 - PubMed
  6. J Reprod Immunol. 2016 Aug;116:7-12 - PubMed
  7. Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S104-8 - PubMed
  8. Nature. 2007 Feb 22;445(7130):866-73 - PubMed
  9. Ann Rheum Dis. 2017 Jun;76(6):960-977 - PubMed
  10. Z Rheumatol. 2002 Dec;61(6):718-27 - PubMed
  11. J Rheumatol Suppl. 2015 Nov;93:70-2 - PubMed
  12. J Eur Acad Dermatol Venereol. 2003 May;17(3):257-70 - PubMed
  13. Clin Exp Dermatol. 2001 Jun;26(4):314-20 - PubMed
  14. RMD Open. 2015 Jun 25;1(1):e000119 - PubMed

Publication Types